BPA for prolastin C

Active Awarded Last action

Contract number
36E79722A0019
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Last date to order 90% complete
IDV ceiling
$107,500,000.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This Blanket Purchase Agreement, awarded to Grifols USA LLC on May 1, 2022, establishes a single-award indefinite delivery vehicle for the procurement of PROLASTIN-C, an alpha1-proteinase inhibitor indicated for treatment of alpha1-antitrypsin deficiency. The contract carries a ceiling value of $107.5 million with an ultimate completion date of April 30, 2027, and is funded through the National Acquisition Center, a civilian federal agency. As a firm fixed-price contract awarded without set-aside provisions, this BPA reflects Grifols' established status as a large business capable of meeting specialized pharmaceutical requirements. The contract falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), leveraging the General Services Administration's master schedule framework to streamline federal procurement of this critical therapeutic agent across multiple federal medical facilities and agencies.

PROLASTIN-C is a plasma-derived therapeutic indicated for chronic augmentation and maintenance therapy in patients with alpha1-antitrypsin deficiency, a genetic disorder affecting lung function. As the primary supplier of this specialized pharmaceutical through this multi-year vehicle, Grifols USA LLC will fulfill delivery orders issued by federal agencies, including the Department of Veterans Affairs and other civilian healthcare entities, enabling efficient procurement without repetitive solicitation processes. The five-year performance period reflects the long-term commitment required to ensure reliable supply chain continuity for patients dependent on this rare disease therapeutic. This BPA represents a significant component of Grifols' federal healthcare contracting portfolio and underscores the critical role of plasma-derived pharmaceutical manufacturers in supporting federal agency medical supply requirements.

Transactions

Action Obligated Date
Exercise an Option P00012 · Exercise option year 4 - BPA 36E79722A0019 $0
Supplemental Agreement for work within scope P00011 · 2026 public law pricing updates. $0
Exercise an Option P00010 · Exercise option year 3 $0
Supplemental Agreement for work within scope P00009 · 2025 public law pricing updates $0
Supplemental Agreement for work within scope P00008 · Prolastin C ordering form update $0
Exercise an Option P00007 · Exercise option year 2 $0
Supplemental Agreement for work within scope P00006 · Temporary price reduction - prolastin $0
Supplemental Agreement for work within scope P00005 · 2024 public law pricing updates $0
Exercise an Option P00004 · Exercise the first option year on BPA 36E79722A0019 $0
Supplemental Agreement for work within scope P00003 · Prolastin C temporary price reduction $0
Supplemental Agreement for work within scope P00002 · 2023 public law pricing updates $0
Other Administrative Action P00001 · Update ordering forms for prolastin C $0
Original award $0
Show all 13

Quick answers

Who was awarded contract 36E79722A0019?

36E79722A0019 was awarded to Grifols USA LLC by National Acquisition Center (Headquarters) on May 1, 2022.

How much is contract 36E79722A0019 worth?

36E79722A0019's own ceiling is $107,500,000.

Who can order from contract 36E79722A0019?

36E79722A0019 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79722A0019 under another contract?

Yes. 36E79722A0019 is a blanket purchase agreement under 36F79722D0090, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79722A0019 competed?

The extent of competition for 36E79722A0019 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV